Novel Oral Anticoagulants for the Treatment of Venous Thromboembolism in Cancer Patients

키워드

참고문헌 (128)

1. Blom JW, "Malignancies, prothrombotic mutations, and the risk of venous thrombosis", JAMA, 293(3), pp.715~722 (2005)
2. Chew HK, "Incidence of venous thromboembolism and its effect on survival among patients with common cancers", Arch Intern Med, 166(4), pp.458~464 (2006)
3. Rickles FR, "Hemostatic alterations in cancer patients", Cancer Metastasis Rev, 11(3-4), pp.237~248 (1992)
4. Khorana AA, "Venous thromboembolism and prognosis in cancer", Thromb Res, 125(6), pp.490~493 (2010)
5. Sorensen HT, "Prognosis of cancers associated with venous thromboembolism", N Engl J Med, 343(25), pp.1846~1850 (2000)
6. Timp JF, "Epidemiology of cancerassociated venous thrombosis", Blood, 122(10), pp.1712~1723 (2013)
7. Falanga A, "Anticancer treatment and thrombosis", Thromb Res, 129(3), pp.353~359 (2012)
8. Hawbaker S, "Venous thromboembolism in the cancer population:pathology, risk, and prevention", J Adv Pract Oncol, 3(1), pp.23~ (2012)
9. Farge D, "International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer", J Thromb Haemostasis, 11(11), pp.56~70 (2013)
10. Lyman GH, "Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update", J Clin Oncol, 31(17), pp.2189~2204 (2013)
11. Mandala M, "Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines", Ann Oncol, 22(suppl6), pp.vi85~vi92 (2011)
12. Akl EA, "Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer", Cochrane Database Syst Rev, 7, pp.1~70 (2014)
13. Kakkar AK, "Venous thrombosis in cancer patients: insights from the FRONTLINE survey", Oncologist, 8(4), pp.381~388 (2003)
14. Delate T, "Outpatient use of low molecular weight heparin monotherapy for first-line treatment of venous thromboembolism in advanced cancer", Oncologist, 17(3), pp.419~427 (2012)
15. Imberti D, "Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry", Haematologica, 93(2), pp.273~278 (2008)
16. Kearon C, "Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)", Chest, 133(suppl6), pp.454s~545s (2008)
17. Rahme E, "Anticoagulant use in patients with cancer associated venous thromboembolism: A retrospective cohort study", Thromb Res, 131(3), pp.210~217 (2013)
18. Dogliotti A, "Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin", Clin Cardiol, 36(2), pp.61~67 (2013)
19. Larsen TB, "Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study", Br Med J, 353, pp.1~9 (2016)
20. Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials", Lancet, 383(9921), pp.955~962 (2014)
21. Wharin C, "Management of venous thromboembolism in cancer patients and the role of the new oral anticoagulants", Blood Rev, 28(1), pp.1~8 (2014)
22. Yeh CH, "Overview of the new oral anticoagulants:opportunities and challenges", Arterioscler. Thromb Vasc Biol, 35(5), pp.1056~1065 (2015)
23. van Es N, "Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study", Thromb Haemost, 114(6), pp.1268~1276 (2015)
24. Young A, "Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism", Thromb Res, 140(suppl1), pp.S172~S173 (2016)
25. Agnelli G, "Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial", J Thromb Haemost, 13(12), pp.2187~2191 (2015)
26. Prins MH, "Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials", Lancet Haematol, 1(1), pp.e37~e46 (2014)
27. Raskob GE, "Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, doubledummy trial", Lancet Haematol, 3(8), pp.e379~e387 (2016)
28. Schulman S, "Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer", Thromb Haemost, 114(1), pp.150~157 (2015)
29. Sardar P, "Efficacy and safety of new oral anticoagulants for extended treatment of venous thromboembolism:systematic review and meta-analyses of randomized controlled trials", Drugs, 73(11), pp.1171~1182 (2013)
30. Vedovati MC, "Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis", Chest, 147(2), pp.475~483 (2015)
31. Raskob G, "Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials", J Thromb Haemost, 11(7), pp.1287~1294 (2013)
32. Bounameaux H, "Edoxaban: an update on the new oral direct factor Xa inhibitor", Drugs, 74(11), pp.1209~1231 (2014)
33. Dobesh PP, "New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities", Drugs, 74(17), pp.2015~2032 (2014)
34. Lee AYY, "Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer", N Engl J Med, 349(2), pp.146~153 (2003)
35. Becattini C, "Treatment of venous thromboembolism with new anticoagulant agents", J Am Coll Cardiol, 67(16), pp.1941~1955 (2016)
36. Schulman S, "Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism", N Engl J Med, 368(8), pp.709~718 (2013)
37. Piatek C, "Treating venous thromboembolism in patients with cancer", Expert Rev Hematol, 5(2), pp.201~209 (2012)
38. Harper P, "Bleeding risk with dabigatran in the frail elderly", N Engl J Med, 366(9), pp.864~866 (2012)
39. King AE, "Dabigatran-associated intracranial hemorrhage: literature review and institutional experience", Neurohospitalist, 5(4), pp.234~244 (2015)
40. Wychowski MK, "Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment", Ann Pharmacother, 46(4), pp.e10~ (2012)
41. Çaliskan F, "Rivaroxaban-induced severe diffuse intracerebral hemorrhage", Am J Emerg Med, 33(3), pp.e471~ (2015)
42. T. Kato, "Cerebral infarction accompanied by cerebral bleeding in patients receiving apixaban", Case Reports, 2015(jan16 1), pp.bcr2014208965~bcr2014208965 (2015), BMJ[DOI]
43. Molina M, "Intracranial hemorrhage in patient treated with rivaroxaban", Hematol Rep, 6(1), pp.5283~ (2014)
44. Sardar P, "New oral anticoagulants in elderly adults: evidence from a meta-Analysis of randomized trials", J Am Geriatr Soc, 62(5), pp.857~864 (2014)
45. Kato ET, "Efficacy and safety of edoxaban for the management of elderly patients with atrial fibrillation: ENGAGE AF-TIMI 48", Circulation, 130(suppl2), pp.A16612~ (2014)
46. Shoeb M, "Assessing Bleeding Risk in Patients Taking Anticoagulants", J Thromb Thrombolysis, 35(3), pp.312~319 (2013)
47. Faraoni D, "Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants", Crit Care, 19(1), pp.1~6 (2015)
48. Prandoni P, "Treatment of patients with acute deep vein thrombosis and", or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations, 2014, pp.134(2), 227~233
49. Laurent Bertoletti, "Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism", Pharmacological Research (2016), Elsevier BV[DOI]
50. Mauer AC, "Impact of sex, age, race, ethnicity and aspirin use on bleeding symptoms in healthy adults", J Thromb Haemost, 9(1), pp.100~108 (2011)
51. Takach LS, "Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis", J Thromb Haemost, 12(5), pp.595~605 (2014)
52. Blanco-Molina A, "Sex differences in patients receiving anticoagulant therapy for venous thromboembolism", Medicine, 93(17), pp.309~317 (2014)
53. Alotaibi GS, "Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis", Thromb Res, 132(2), pp.185~189 (2013)
54. Dentali F, "Gender difference in efficacy and safety of nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation or venous thromboembolism: a systematic review and a meta-analysis of the literature", Semin Thromb Hemost, 41(17), pp.774~787 (2015)
55. Loffredo L, "Sex related differences in patients with acute venous thromboembolism treated with new oral anticoagulants. A metaanalysis of the interventional trials", Int J Cardiol, 212, pp.255~258 (2016)
56. Agnelli G, "Oral apixaban for the treatment of acute venous thromboembolism", N Engl J Med, 369, pp.799~808 (2013)
57. Bauersachs RM, "Guidelines for the management of cancer and thrombosis - Special aspects in women", Thromb Res, 135, pp.S16~S22 (2015)
58. Burnett AE, "Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment", J Thromb Thrombolysis, 41(1), pp.206~232 (2016)
59. Pokorney SD, "Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation", J Thromb Thrombolysis, 36(2), pp.163~174 (2013)
60. Kubitza D, "Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects", J Clin Pharmacol, 47(2), pp.218~226 (2007)
61. Upreti VV, "Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects", Br J Clin Pharmacol, 76(6), pp.908~916 (2013)
62. Lip GY, "Edoxaban: a focused review of its clinical pharmacology", Eur Heart J, 35(28), pp.1844~1855 (2014)
63. Macedo AF, "Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink", Thromb Res, 136(2), pp.250~260 (2015)
64. Aapro M, "Importance of monitoring renal function in patients with cancer", Cancer Treat Rev, 38(3), pp.235~240 (2012)
65. Launay-Vacher V, "Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management", Cancer, 110(6), pp.1376~1384 (2007)
66. Lichtman SM, "International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency", Eur J Cancer, 43(1), pp.14~34 (2007)
67. Reilly PA, "The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)", J Am Coll Cardiol, 63(4), pp.321~328 (2014)
68. Stangier J, "Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate", Clin Pharmacokinet, 49(4), pp.259~268 (2010)
69. Safouris A, "The case for dosing dabigatran:how tailoring dose to patient renal function, weight and age could improve the benefit–risk ratio", Ther Adv Neurol Disord, 8(6), pp.245~254 (2015)
70. Hughes S, "Anticoagulation in chronic kidney disease patients—the practical aspects", Clin Kidney J, 7(5), pp.442~449 (2014)
71. Kubitza D, "Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor", Br J Clin Pharmacol, 70(5), pp.703~712 (2010)
72. Wasserlauf G, "Meta-analysis of rivaroxaban and bleeding risk", Am J Cardiol, 112(3), pp.454~460 (2013)
73. Weinz C, "Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans", Drug Metab Dispos, 37(5), pp.1056~1064 (2009)
74. Beyer-Westendorf J, "Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry", Blood, 124(6), pp.955~962 (2014)
75. Tamayo S, "Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban", Clin Cardiol, 38(2), pp.63~68 (2015)
76. Raghavan N, "Apixaban metabolism and pharmacokinetics after oral administration to humans", Drug Metab Dispos, 37(1), pp.74~81 (2009)
77. Chang M, "Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban", J Clin Pharmacol, 56(5), pp.637~645 (2016)
78. Hohnloser SH, "Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial", Eur Heart J, 33(22), pp.2821~2830 (2012)
79. Pathak R, "Meta-analysis on risk of bleeding with apixaban in patients with renal impairment", Am J Cardiol, 115(3), pp.323~327 (2015)
80. Harel Z, "Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD", J Am Soc Nephrol, 25(3), pp.431~442 (2014)
81. Giugliano RP, "Edoxaban versus warfarin in patients with atrial fibrillation", N Engl J Med, 369(22), pp.2093~2104 (2013)
82. Koretsune Y, "Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment", Eur Heart J, 34(suppl1), pp.520~ (2013)
83. Agnelli G, "Safety assessment of new antithrombotic agents: Lessons from the EXTEND study on ximelagatran", Thromb Res, 123(3), pp.488~497 (2009)
84. Mekaj YH, "New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events", Ther Clin Risk Manage, 11, pp.967~977 (2015)
85. Graff J, "Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment", Clin Pharmacokinet, 52, pp.243~254 (2013)
86. Mueck W, "Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban", Clin Pharmacokinet, 53(1), pp.1~16 (2014)
87. Stangier J, "Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment", J Clin Pharmacol, 48(12), pp.1411~1419 (2008)
88. Caldeira D, "Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis", Heart, 100, pp.550~556 (2014)
89. Schulman S, "Dabigatran versus warfarin in the treatment of acute venous thromboembolism", N Engl J Med, 361(24), pp.2342~2352 (2009)
90. Connolly SJ, "Dabigatran versus warfarin in patients with atrial fibrillation", N Engl J Med, 361(12), pp.1139~1151 (2009)
91. Liakoni E, "Hepatotoxicity of New Oral Anticoagulants (NOACs)", Drug Saf, 38(8), pp.711~720 (2015)
92. Kim RB, "Drugs as P-glycoprotein substrates, inhibitors, and inducers", Drug Metab Rev, 34(1-2), pp.47~54 (2002)
93. Samer CF, "Applications of CYP450Testing in the Clinical Setting", Mol Diagn Ther, 17(3), pp.165~184 (2013)
94. Short NJ, "New oral anticoagulants and the cancer patient", Oncologist, 19(1), pp.82~93 (2014)
95. Stöllberger C, "Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban", Herz, 40(2), pp.140~145 (2015)
96. Stangier J, "Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor", Clin Appl Thromb Hemost, 15(suppl1), pp.9S~16S (2009)
97. Hellwig T, "Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants", Ann Pharmacother, 47(11), pp.1478~1487 (2013)
98. Nutescu E, "Drug and dietary interactions of warfarin and novel oral anticoagulants: an update", J Thromb Thrombolysis, 31(3), pp.326~343 (2011)
99. Mendell J, "Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor", Am J Cardiovasc Drugs, 13(5), pp.331~342 (2013)
100. Mikkaichi T, "Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition", Drug Metab Dispos, 42(4), pp.520~528 (2014)
101. Pare G, "Genetic determinants of dabigatran plasma levels and their relation to bleeding", Circulation, 127, pp.1402~1412 (2013)
102. Legrand M, "The use of dabigatran in elderly patients", Arch Intern Med, 171(14), pp.1285~1286 (2011)
103. Parasrampuria DA, "Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa", Clin Pharmacokinet, 55(6), pp.641~655 (2016)
104. Stangier J, "No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin", J Thromb Haemost, 5(suppl2), pp.w672~ (2007)
105. Frost CE, "Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor", Br J Clin Pharmacol, 79(5), pp.838~846 (2015)
106. Altena R, "Clinical challenges related to novel oral anticoagulants: drug-drug interactions and monitoring", Haematologica, 99(2), pp.eE26~e27 (2014)
107. Vakkalagadda B, "Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa", Am J Cardiovasc Drugs, 16(2), pp.119~127 (2016)
108. Härtter S, "Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin", Br J Clin Pharmacol, 74(3), pp.490~500 (2012)
109. Mendell J, "The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults", Clin Drug Invest, 35(7), pp.447~453 (2015)
110. Lam MS, "A guide to clinically relevant drug interactions in oncology", J Oncol Pharm Pract, 9(2-3), pp.45~85 (2003)
111. Mavrakanas T, "Direct oral anticoagulants:efficacy and safety in patient subgroups", Swiss Med Wkly, 145, pp.w14081~ (2015)
112. Riechelmann RP, "Drug interactions in oncology:how common are they?", Ann Oncol (2009)[DOI]
113. Holbrook A, "Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidencebased clinical practice guidelines", Chest, 141(suppl2), pp.e152S~e184S (2012)
114. Steiner T, "Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban", Clin Res Cardiol, 102(6), pp.399~412 (2013)
115. Eerenberg ES, "Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate a randomized, placebo-controlled, crossover study in healthy subjects", Circulation, 124(14), pp.1573~1579 (2011)
116. Marlu R, "Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban", Thromb Haemost, 108(2), pp.217~224 (2012)
117. Sarich TC, "Novel oral anticoagulants and reversal agents: Considerations for clinical development", Am Heart J, 169(6), pp.751~757 (2015)
118. Suryanarayan D, "Potential antidotes for reversal of old and new oral anticoagulants", Thromb Res, 133, pp.S158~S166 (2014)
119. Lazo-Langner A, "Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications", Crit Care, 17(3), pp.230~ (2013)
120. Schiele F, "A specific antidote for dabigatran:functional and structural characterization", Blood, 121(18), pp.3554~3562 (2013)
121. Glund S, "A specific antidote for dabigatran:immediate, complete and sustained reversal of dabigatran induced anticoagulation in healthy male volunteers", Circulation, 128(suppl22), pp.A17765~ (2013)
122. Glund S, "Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects", Blood, 124(21), pp.344~ (2014)
123. Pollack CVJ, "Idarucizumab for Dabigatran Reversal", N Engl J Med, 373(6), pp.511~520 (2015)
124. Schwarb H, "New direct oral anticoagulants (DOAC)and their use today", Dent J, 4(1), pp.5~ (2016)
125. Siegal DM, "Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents", J Thromb Thrombolysis, 39(3), pp.395~402 (2015)
126. Hu TY, "Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab", Vasc Health Risk Manage, 12, pp.35~ (2016)
127. Siegal DM, "Andexanet alfa for the reversal of factor Xa inhibitor activity", N Engl J Med, 373(25), pp.2413~2424 (2015)
128. Bauer KA, "Targeted anti-anticoagulants", N Engl J Med, 373(6), pp.569~571 (2015)

관련 논문AI추천